ClinicalTrials.gg

Program

UTAA07

A development code. Also written as “UTAA07 injection”.

Its studies are led by PersonGen BioTherapeutics (Suzhou).

Furthest: early phase 1, since Dec 16, 20251 company-led study, 1 open or runningNext primary completion: Dec 31, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PersonGen BioTherapeutics (Suzhou)11 open or runningearly phase 1since Dec 16, 2025Dec 16, 2025Dec 31, 2027early phase 1 · NCT07338604

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2025First study: early phase 1 study in Hematolymphoid MalignanciesFirst studyNCT07338604 · 15 planned · China

Ahead

  1. Dec 31, 2027Primary completion: early phase 1 study in Hematolymphoid MalignanciesNCT07338604

TargetBeta

CD7 →read by rule
“UTAA07 Injection is a chimeric antigen receptor (CAR)-engineered γδ T-cell product that targets the CD7 antigen expressed on the surface of tumor cells.”study text, by rule · the study

Other programs on CD7

ProgramCompanyFurthest phaseStudies
Autologous Anti-CD7 CAR T Cells PA3-17rulePersonGen BioTherapeutics (Suzhou)phase 26
Anti-CD7 CAR-T Cells RD13-02rulenanjing-bioheng-biotech-co-ltdearly phase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07338604Hematolymphoid Malignancies · ChinaEarly 1RecruitingDec 31, 202715

How it is read

Names in the registry

  • “UTAA07 injection”, 1 entry

Codes read as this program: UTAA07.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.